FDA clears Fujifilm Sonosite POCUS for COVID-19 use

By AuntMinnie.com staff writers

September 3, 2020 -- Ultrasound developer Fujifilm SonoSite has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the use of its point-of-care ultrasound (POCUS) for performing lung and cardiac imaging of COVID-19 patients.

In announcing the clearance, Fujifilm Sonosite notes that POCUS has emerged as a portable, efficient tool for examining patients suspected of having COVID-19 at the point of care. The 510(k) clearance applies to the company's entire POCUS portfolio.

In conjunction with the FDA's move, the company released a user guide to help healthcare providers in how to best use POCUS to interpret ultrasound images to recognize the most common COVID-19 findings with respect to lung and cardiac conditions.

Copyright © 2020 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking